Fludarabine, Cytarabine, Filgrastim, Gemtuzumab Ozogamicin, and Idarubicin for Leukemia/Myelodysplastic Syndrome
Phase 2
270
about 22 years
18+
1 site in TX
What this study is about
This trial is testing a treatment with fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride in people with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal of this treatment is to kill cancer cells and improve outcomes.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Laboratory Biomarker Analysis
- 2.Receive Filgrastim-sndz
- 3.Take Cytarabine
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cytarabine, decitabine, Blood Products/Modifiers/Volume Expanders (Receptor Activity Modifying Protein Agonists), Antineoplastic Agent [TC] (Nucleic Acid Synthesis Inhibitors), gemtuzumab ozogamicin, idarubicin
injection (Injection), injection, intravenous
Primary: Complete remission rate, Toxicity rate
Oncology